232 related articles for article (PubMed ID: 22641286)
1. Targeted molecular therapies for ovarian cancer: an update and future perspectives (Review).
Shigetomi H; Higashiura Y; Kajihara H; Kobayashi H
Oncol Rep; 2012 Aug; 28(2):395-408. PubMed ID: 22641286
[TBL] [Abstract][Full Text] [Related]
2. Promising molecular targets in ovarian cancer.
Blagden S; Gabra H
Curr Opin Oncol; 2009 Sep; 21(5):412-9. PubMed ID: 19553815
[TBL] [Abstract][Full Text] [Related]
3. The future of targeted therapies in ovarian cancer.
Banerjee S; Gore M
Oncologist; 2009 Jul; 14(7):706-16. PubMed ID: 19592450
[TBL] [Abstract][Full Text] [Related]
4. Leveraging DNA repair deficiency in gynecologic oncology.
Walsh CS; Hodeib M
Curr Opin Obstet Gynecol; 2016 Feb; 28(1):24-31. PubMed ID: 26694829
[TBL] [Abstract][Full Text] [Related]
5. New insights on the pathogenesis of ovarian carcinoma: molecular basis and clinical implications.
Gadducci A; Guerrieri ME; Genazzani AR
Gynecol Endocrinol; 2012 Aug; 28(8):582-6. PubMed ID: 22304686
[TBL] [Abstract][Full Text] [Related]
6. The role of targeted therapy in ovarian cancer.
Banerjee S; Kaye S
Eur J Cancer; 2011 Sep; 47 Suppl 3():S116-30. PubMed ID: 21943965
[TBL] [Abstract][Full Text] [Related]
7. New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential.
Banerjee S; Kaye SB
Clin Cancer Res; 2013 Mar; 19(5):961-8. PubMed ID: 23307860
[TBL] [Abstract][Full Text] [Related]
8. Targeting genetic and epigenetic alterations in the treatment of serous ovarian cancer.
Weberpals JI; Koti M; Squire JA
Cancer Genet; 2011 Oct; 204(10):525-35. PubMed ID: 22137482
[TBL] [Abstract][Full Text] [Related]
9. Participation of the ATR/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer.
Gralewska P; Gajek A; Marczak A; Rogalska A
J Hematol Oncol; 2020 Apr; 13(1):39. PubMed ID: 32316968
[TBL] [Abstract][Full Text] [Related]
10. The role of poly adenosine diphosphate ribose polymerase inhibitors in breast and ovarian cancer: current status and future directions.
Chionh F; Mitchell G; Lindeman GJ; Friedlander M; Scott CL
Asia Pac J Clin Oncol; 2011 Sep; 7(3):197-211. PubMed ID: 21884432
[TBL] [Abstract][Full Text] [Related]
11. [New drugs and targeted therapeutic agents in ovarian cancer].
de La Motte Rouge T; Petrella MC; Michels J; Even C; Balleyguier C; Duclos J; Mazeron R; Morice P; Pautier P; Lhommé C
Bull Cancer; 2009 Dec; 96(12):1215-24. PubMed ID: 19919916
[TBL] [Abstract][Full Text] [Related]
12. Novel targeted agents for the treatment of advanced breast cancer.
de la Vega M; Díaz-Cantón E; Alvarez RH
Future Med Chem; 2012 May; 4(7):893-914. PubMed ID: 22571614
[TBL] [Abstract][Full Text] [Related]
13. Defining and targeting wild-type BRCA high-grade serous ovarian cancer: DNA repair and cell cycle checkpoints.
Ivy SP; Kunos CA; Arnaldez FI; Kohn EC
Expert Opin Investig Drugs; 2019 Sep; 28(9):771-785. PubMed ID: 31449760
[No Abstract] [Full Text] [Related]
14. Investigational agents for epithelial ovarian cancer.
Muggia F; Kosloff R
Expert Rev Anticancer Ther; 2005 Oct; 5(5):855-68. PubMed ID: 16221055
[TBL] [Abstract][Full Text] [Related]
15. Targeted agents and combinations in ovarian cancer: where are we now?
McLachlan J; Lima JP; Dumas L; Banerjee S
Expert Rev Anticancer Ther; 2016; 16(4):441-54. PubMed ID: 26942837
[TBL] [Abstract][Full Text] [Related]
16. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.
Dressman HK; Berchuck A; Chan G; Zhai J; Bild A; Sayer R; Cragun J; Clarke J; Whitaker RS; Li L; Gray J; Marks J; Ginsburg GS; Potti A; West M; Nevins JR; Lancaster JM
J Clin Oncol; 2007 Feb; 25(5):517-25. PubMed ID: 17290060
[TBL] [Abstract][Full Text] [Related]
17. New strategies for the treatment of ovarian cancer.
Robinson E; Fisher N; Stamelos V; Redman C; Richardson A
Biochem Soc Trans; 2014 Feb; 42(1):125-9. PubMed ID: 24450639
[TBL] [Abstract][Full Text] [Related]
18. The promise and perils of 'targeted therapy' of advanced ovarian cancer.
Markman M
Oncology; 2008; 74(1-2):1-6. PubMed ID: 18536523
[TBL] [Abstract][Full Text] [Related]
19. Targeting homologous repair deficiency in breast and ovarian cancers: Biological pathways, preclinical and clinical data.
Chartron E; Theillet C; Guiu S; Jacot W
Crit Rev Oncol Hematol; 2019 Jan; 133():58-73. PubMed ID: 30661659
[TBL] [Abstract][Full Text] [Related]
20. The potential of PARP inhibitors in genetic breast and ovarian cancers.
Drew Y; Calvert H
Ann N Y Acad Sci; 2008 Sep; 1138():136-45. PubMed ID: 18837894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
